KeriCure
Wesley Chapel
About KeriCure
KeriCure is a cutting edge biotech company that is solving the problem of infection control in the consumer, animal health and medical wound care markets. Application of our nanopolymer technology can provide significant impact on overall healing outcomes and reduce infection rates, saving thousands on medical and veterinary bills. KeriCure's goal is to breathe new life into the stagnant wound care market, where there is expansive market potential and growth capabilities. The current global wound care market is a $60B combined market in consumer, animal health and medical market channels, where the number one concern is preventing infections. Even minor cuts can turn into a serious, life threatening infection, and the majority of products available do not effective prevent infections and require harsh chemicals. Through application of KeriCure's nanopolymer technology, we are able to provide effective wound care solutions to combat infections. Our newest technology incorporates antimicrobial nanosilver for added benefits well recognized in the consumer & medical markets. KeriCure's secure IP and FDA clearances put us in a prime position for channel partnerships with biotech, pharma and animal health companies, with the ultimate goal of acquisition. A combined $60B global wound care market spanning OTC, animal and medical channels, where KeriCure is in a position to secure 1% of the global market through channel partnerships. Dr. Greenhalgh and her team of business leaders, regulatory experts, and strategic advisors have positioned KeriCure for rapid growth and success.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.9M
- Funding stage: Seed
- Last round: Seed (Nov 2018)
- Website: kericuremedical.com
- Phone: (855) 888-5374
Industries & Categories
Biotechnology, Consumer, Consumer Goods, Elder Care, First Aid
Social Profiles
Canonical: https://fsome.com/organization/kericure-70864 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.